Recombinant Human LOX-1 Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-3219

Recombinant Human LOX-1 Protein (His Tag)

Beta LifeScience SKU/CAT #: BLPSN-3219
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Tag His
Host Species Human
Accession P78380
Background Oxidized low-density lipoprotein receptor 1 (Ox-LDL receptor 1 or OLR1), also known as lectin-type oxidized LDL receptor 1 (LOX1), is a receptor protein that belongs to the C-type lectin superfamily. LOX1 is a multi-ligand receptor originally identified as the endothelial oxidized LDL receptor. OLR1 / LOX1 was isolated from an aortic endothelial cell, and recently it has been discovered in macrophages and vascular smooth muscle cells in artery vessels. The expression of LOX1 is inducted by inflammatory stimuli and oxidative stimuli. This protein binds, internalizes and degrades oxidized low-density lipoprotein. LOX1 may play an important role in the progression of vulnerable carotid plaque and might regulate vulnerable plaque formation in cooperation with MMPs and TIMP-2. In clinical, LOX1 is thought to be involved in the development of atherosclerotic lesions.
Description A DNA sequence encoding the human OLR1 (P78380) extracellular domain (Ser 61-Gln 273) was expressed, with a His tag at the N-terminus.
Source HEK293
Predicted N Terminal His
AA Sequence Ser 61-Gln 273
Molecular Weight The recombinant human OLR1 consists of 229 a.a. and has a calculated molecular mass of 26.5 kDa. It exists as a disulfide-linked homodimer. As a result of glycosylation, the apparent molecular mass of rhOLR1 is approximately 30-35 kDa in SDS-PAGE under reducing conditions, and 60-70 kDa in non-reduced SDS-PAGE.
Purity >85% as determined by SDS-PAGE
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method
Bioactivity Please contact us for detailed information
Formulation Lyophilized from sterile PBS, pH 7.4.
Stability The recombinant proteins are stable for up to 1 year from date of receipt at -70°C.
Usage For Research Use Only
Storage Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Target Details

Target Function Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria.
Subcellular Location Cell membrane; Lipid-anchor. Cell membrane; Single-pass type II membrane protein. Membrane raft. Secreted. Note=A secreted form also exists. Localization to membrane rafts requires palmitoylation.
Database References
Associated Diseases Independent association genetic studies have implicated OLR1 gene variants in myocardial infarction susceptibility.; DISEASE: Note=OLR1 may be involved in Alzheimer disease (AD). Involvement in AD is however unclear: according to some authors (PubMed:12354387, PubMed:12810610 and PubMed:15976314), variations in OLR1 modify the risk of AD, while according to other (PubMed:15000751 and PubMed:15060104) they do not.
Tissue Specificity Expressed at high level in endothelial cells and vascular-rich organs such as placenta, lung, liver and brain, aortic intima, bone marrow, spinal cord and substantia nigra. Also expressed at the surface of dendritic cells. Widely expressed at intermediate

Gene Functions References

  1. Study showed that a high expression of LOX-1 was associated with poor prognosis in gastric cancer (GC) patients and TNM stage. LOX-1 was found to promote migration, invasion and epithelial-mesenchymal transition (EMT) of GC cells through activating PI3K/Akt/GSK3beta pathway. PMID: 28345638
  2. LOX-1(+) CD15(+) polymorphonuclear myeloid-derived suppressor cells were elevated in hepatocellular carcinoma patients and suppressed T cell proliferation through ROS/Arg I pathway induced by ER stress. PMID: 29211299
  3. High LOX-1 ligand activity as a risk factor for ischemic stroke. PMID: 28442661
  4. The analysis also revealed that OLR1 is not required for the transcriptional regulation induced by oxidized PAPC but interestingly, OLR1 knockdown affected expression of CNN2, HMRR, ITGB6 and KIF20A, all genes governing cell proliferation and motility. PMID: 29103984
  5. Data show that oxidized low density lipoprotein receptor 1 (LOX-1) is overexpressed in prostate cancer cells. PMID: 29107109
  6. expression significantly higher in the arterial wall of epicardial coronary arteries compared to intramyocardial coronary arteries PMID: 29448251
  7. let7g exerts a LOX1independent antiaging effect on endothelial cells. PMID: 29393358
  8. high LOX-1 expression in pancreatic cancer tissues is indicative for the occurrence of lymph node metastases, high TNM stages and a poor prognosis. PMID: 29168159
  9. lincRNAp21 is a major mediator of oxLDLinduced apoptosis and expression of LOX1 in human vascular endothelial cells, and acts via activation of PKCdelta. PMID: 28983628
  10. this study shows that LOX-1 is involved in IL-1beta production and extracellular matrix breakdown in dental peri-implantitis PMID: 28898769
  11. Results showed that the scFv with N-terminal fusing peptides proteins demonstrated increased LOX-1-binding activity without decrease in stability. These findings will help increase the application efficacy of LOX-1 targeting scFv in LOX-1-based therapy PMID: 29094051
  12. The serum sLOX-1 level was higher in patients with large artery atherosclerotic stroke, and it was an independent predictor of functional outcome in patients with large artery atherosclerotic ischemic stroke. PMID: 27967338
  13. LOX-1 has a role in atherogenesis and tumorigenesis as a potential link in these diseases [review] PMID: 29462603
  14. the rs1050283 T allele of LOX-1 is strongly associated with an increased risk for atherosclerotic cerebral infarction in a Chinese population, which also affects levels of LOX-1 and sLOX-1 PMID: 27840386
  15. data revealed that miR-let-7g exhibits anti-atherosclerotic activity, at least partially by targeting the LOX-1 signaling pathway. PMID: 28535009
  16. High LOX1 expression is associated with colorectal cancer. PMID: 26895376
  17. Increased LOX-1 expression in endothelial cells is potentially involved in the pathogenesis of sickle cell disease vasculopathy PMID: 27519944
  18. LOX-1 signalling and the crucial role of cytokines PMID: 28860004
  19. High OLR1 expression is associated with breast cancer. PMID: 28844714
  20. Multiple classical molecular dynamics simulations have been applied to the human LOX-1 receptor to clarify the role of the Trp150Ala mutation in the loss of binding activity. Results indicate that the substitution of this crucial residue, located at the dimer interface, markedly disrupts the wild-type receptor dynamics PMID: 28657156
  21. Carrying the C allele of the rs11053646 variant of the OLR1 gene was associated with an increased risk of CAD in heterozygous adult patients with FH, and this risk could be even greater in smokers as well as in younger patients. PMID: 28941610
  22. Berberine could prevent the oxLDL and TNFalpha - induced LOX1 expression and oxidative stress, key events that lead to NOX, MAPK/Erk1/2 and NF-kappaB activation linked to endothelial dysfunction. PMID: 28511903
  23. Individuals >/=30 years old with abdominal obesity presented lower Lox1 levels than patients >/=30 years old without abdominal obesity. PMID: 27525284
  24. These studies suggest that activation of LOX-1 expression occurs through binding of the chlamydial glycan and provides one mechanism by which Chlamydia pneumoniae infection could play a role in the pathogenesis of atherosclerosis. PMID: 23821487
  25. Elevated LOX1 is Associated with Acute Stroke. PMID: 27025681
  26. Xanthine oxidase induces foam cell formation in large part through activation of LOX-1 - NLRP3 pathway in both vascular smooth muscle cells and THP-1 cells. PMID: 28084571
  27. show that MiR-590-5p inhibits angiogenesis by targeting LOX-1 and suppressing redox-sensitive signals PMID: 26932825
  28. OLR1 rs1050286 SNP may contribute to modify OLR1 susceptibility to acute myocardial infarction and coronary artery diseases. PMID: 26542080
  29. Serum sLOX-1 level was significantly lower in the restless legs syndrome patient group compared to controls. PMID: 27546362
  30. The mechanistic link between miR-590-5p and LOX-1:miR-590-5p downregulation led to LOX-1 upregulation in endothelial cells. PMID: 26906623
  31. Serum LAB was associated with an increased carotid IMT in Japanese men, especially those with hypercholesterolemia PMID: 26892134
  32. the current meta-analysis highlighted that variant allele of OLR1 rs11053646 G > C and PCSK9 rs505151 A > G may contribute to the susceptibility risk of ischemic stroke. PMID: 26666837
  33. Silencing of LOX-1 gene expression abolished ox-LDL induced effects in cell viability, reactive oxygen species generation and gene expression. PMID: 26510581
  34. both the 501>C single nucleotide polymorphisms in the LOX1 gene and the serum LOX1 level may be used to predict the development of left ventricular hypertrophy among essential hypertension patients. PMID: 24480971
  35. for our Turkish sample group, LOX-1 30UTR188C/T and K167N polymorphisms may not be involved in susceptibility to GDM [gestational diabetes mellitus ] PMID: 26296941
  36. Cholesterol depletion triggers the release of LOX-1 in exosomes as a full-length transmembrane isoform and as a truncated ectodomain soluble fragment. PMID: 26495844
  37. Interaction between Lox-1, C-reactive protein and oxidized LDL play role in the pathogenesis of atherosclerosis. PMID: 26607724
  38. OLR1 is a novel molecular link between the proliferative and inflammatory responses of vascular smooth muscle cells. PMID: 26305474
  39. Ginkgo biloba extract inhibits oxLDL-induced matrix metalloproteinase activation by the modulation of the LOX1-regulated signaling pathway in human umbilical vein endothelial cells. PMID: 25080882
  40. Data show that the interplay between the two TNF receptors (TNFR1 and TNFR2) was apparent in the expression pattern of lectin-type oxidized LDL receptor 1 (LOX-1) in response to TNF-alpha. PMID: 25416967
  41. The serum LOX-1 levels were significantly higher in NAFLD patients than in healthy controls. PMID: 26185381
  42. Low shear stress is a regulator of autophagy and LOX-1 plays an important role in shear stress induced autophagy. PMID: 25697875
  43. results showed higher expression of HSP70 and LOX-1 in the placental tissues of pre-eclampsia patients which represent the possible contribution of these molecules in the disease pathogenesis. PMID: 24786389
  44. Elevated plasma sLOX-1 level on admission independently predicts long-term all-cause mortality and MACE after STEMI. PMID: 25746549
  45. biomarker for determining early endothelial damage in hypertension, especially in white coat hypertension PMID: 25007999
  46. LOX-1 activation by oxLDL is an important event that enhances tumor angiogenesis PMID: 25170920
  47. LOX-1 is the receptor that mediates oxidized LDL activity in vascular endothelial cells.Activation of LOX-1 causes endothelial dysfunction and vascular lipid deposition. PMID: 25463747
  48. Our data indicate a new direction for LOX-1 regulation by the modulation of the PKCbeta/NAPDH oxidase/SIRT1/HSF1 mechanism PMID: 25982096
  49. The present study showed that circulating soluble LOX-1 originates from coronary circulation and soluble LOX-1 and LOX-1 index are useful biomarkers for acute coronary syndrome. PMID: 24895597
  50. Meta-analysis results showed that the +1073 C/T polymorphism in ORL1 decreased the risk of Alzheimer's disease. This allele was predicted to affect the binding site of many miRNAs explaining the relationship between the +1073 C/T variant and the disease. PMID: 25501227


Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed